Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial

David J. Lederer1,2, Nisha Philip1, Debbie Rybak1, Selim M. Arcasoy1, Steven M. Kawut3,4

1 Department of Medicine, College of Physicians and Surgeons, Columbia University, New York City, New York, United States of America, 2 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York City, New York, United States of America, 3 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 4 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

Abstract

Background: We aimed to determine the effects of treatment with intravenous immunoglobulin on bacterial infections in patients with hypogammaglobulinemia (HGG) after lung transplantation.

Methods: We performed a randomized, double-blind, placebo-controlled two-period crossover trial of immune globulin intravenous (IVIG), 10% Purified (Gamunex, Bayer, Elkhart, IN) monthly in eleven adults who had undergone lung transplantation more than three months previously. We randomized study participants to three doses of IVIG (or 0.1% albumin solution (placebo)) given four weeks apart followed by a twelve week washout and then three doses of placebo (or IVIG). The primary outcome was the number of bacterial infections within each treatment period.

Results: IVIG had no effect on the number of bacterial infections during the treatment period (3 during IVIG and 1 during placebo; odds ratio 3.5, 95% confidence interval 0.4 to 27.6, p = 0.24). There were no effects on other infections, use of antibiotics, or lung function. IVIG significantly increased trough IgG levels at all time points (least square means, 765.3 mg/dl during IVIG and 486.3 mg/dl during placebo, p < 0.001). Four serious adverse events (resulting in hospitalization) occurred during the treatment periods (3 during active treatment and 1 during the placebo period, p = 0.37). Chills, flushing, and nausea occurred during one infusion of IVIG.

Conclusions: Treatment with IVIG did not reduce the short-term risk of bacterial infection in patients with HGG after lung transplantation. The clinical efficacy of immunoglobulin supplementation in HGG related to lung transplantation over the long term or with recurrent infections is unknown.

Trial Registration: Clinicaltrials.gov NCT00115778

Introduction

Potent immunosuppressive regimens, consisting of a calcineurin inhibitor, an anti-metabolite, and corticosteroids, predominantly target cell-mediated immunity to prevent lung allograft rejection after lung transplantation. Not surprisingly, lung transplant recipients suffer from an increased risk of infection by pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus, and cytomegalovirus despite intensive antimicrobial prophylaxis [1,2,3,4,5].

Immunosuppressive therapy after solid organ transplantation may also contribute to humoral immunodeficiency due to hypogammaglobulinemia (HGG). [6,7,8,9] A recent meta-analysis suggested that severe HGG after solid organ transplantation is associated with an increased risk of early infection and all-cause mortality. [10] In one study of lung transplant recipients, HGG was identified in 70% of lung transplant recipients, of whom 50% had very low immunoglobulin G (IgG) levels (<400 mg/dL). [9] Bacterial, fungal, and viral infections were significantly more common and survival significantly worse among those with HGG. We previously found that 58% of lung transplant recipients had episodes occurring within the first year of transplantation. [7] In that study, use of mycophenolate mofetil was an independent risk factor for HGG. We have also shown that the presence of HGG is associated with an increased risk of pneumonia, supporting the
clinical importance of HGG in our lung transplant recipients. [8] Moreover, HGG has been reported in recipients of other solid organ transplants, such as heart and kidney, with significant clinical implications [11,12,13].

Intravenous immunoglobulin (IVIG) therapy is the current standard of care for patients with primary and certain secondary immunodeficiency states. Presently, IVIG is FDA-approved for treatment of primary humoral immunodeficiency, Kawasaki syndrome, B-cell chronic lymphocytic leukemia, and bone marrow transplant recipients with recurrent infections, pediatric HIV infection, and idiopathic thrombocytopenic purpura. It is well-established that augmentation of immunoglobulin levels in these immunodeficiency states results in decreases in bacterial infections [14].

IVIG therapy could significantly decrease the incidence and/or severity of infections in lung transplant recipients with HGG, however the use of IVIG in HGG after solid organ transplantation has not been well-studied. Despite the potential benefits, IVIG is relatively difficult to administer (requiring monthly intravenous infusion), has potential adverse reactions, and is very expensive. We performed a pilot phase II clinical trial to determine the efficacy and safety of immunoglobulin supplementation for HGG after lung transplantation.

Materials and Methods

The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.

Ethics Statement

The protocol was approved by the Columbia University Medical Center (CUMC) Institutional Review Board and the medical monitor.

Study Design

This was a single-center, randomized double-blind, placebo-controlled, two-period crossover study to determine the efficacy and safety of IVIG in patients with HGG after lung transplantation. The original protocol called for the recruitment of 10 subjects; we enrolled one additional subject after one dropped out. The first subject was randomized in April 2006 and the last subject by July 2008.

The manuscript was written by the authors, and the decision to submit the manuscript for publication was made solely by the authors. This manuscript was sent to the sponsor before submission for publication, however the sponsor had no right to delay or require any revisions to this manuscript. The sponsor did not participate in data analysis or drafting of the manuscript.

Study Participants

We recruited adult lung transplant recipients at Columbia University Medical Center (CUMC) who were at least 3 months out from lung transplantation and had HGG (IgG levels < 500 mg/dL) on two assessments at least one month apart within three months. Study subjects had to be on a stable medical regimen for at least one month before enrollment. We excluded those with acute rejection (defined histologically) or active infection within one month before enrollment, a contraindication to IVIG (acute renal failure, severe selective IgA deficiency, known hypersensitivity to IVIG), pregnancy, or a history of a thrombotic event within three months. The initial protocol called for IgG levels <400 mg/dL, which was increased to <500 mg/dL due to slow enrollment. All participants provided written informed consent. This study was registered at clinicaltrials.gov before the initiation of enrollment (NCT00115778) [http://clinicaltrials.gov/show/NCT00115778].

Study Procedures

This was a crossover study with two 12 week treatment periods (separated by a 12 week washout period) comparing immune globulin intravenous (Human); 10% Caprylate/Chromatography Purified (Gamunex) (Bayer, Elkhart, IN) ("IVIG") with 0.1% albumin ("placebo"). The in vivo half-life of this form of IVIG is approximately 35 days. The dose of IVIG in this study was 400 mg/kg every 4 weeks, which is a widely used dosage in clinical practice. The initial infusion rate was 0.01 mL/kg/min, titrated to a maximum infusion rate of 0.08 mL/kg/min. Placebo was 0.1% albumin in an equal volume, prepared by the Columbia Research Pharmacy. IVIG and placebo infusion bags had identical color and appearance. All participants were pre-mediated with acetaminophen 650 mg po and diphenhydramine 25 mg po before every study drug infusion.

The Research Pharmacy at Columbia University randomly assigned the treatment order. Investigators, study personnel, and study participants were blinded to the order and identity of the treatments. IgG levels were not performed during the study; samples were banked and then run after the conclusion of the study. Study drug was prepared by an unblinded research pharmacist and delivered to the infusion suite at our medical center where each dose of study drug was administered.

Study participants were evaluated at baseline and at Week 4, 8, 12, 24, 28, 32, and 36. The “Period 1” study drug was administered at baseline and at Week 4 and 8 study visits. The “Period 2” study drug was administered at Week 24, 28, and 32. There was a twelve week washout period between the Period 1 and Period 2. Phlebotomy was performed on the morning of each study visit, before infusion of the study drug. Participants maintained a diary of any new medications or symptoms during the study period.

Outcome Assessments

The primary outcome was the number of bacterial infections during the treatment period. Secondary outcomes included viral, fungal and all non-bacterial infections, hospital admissions, antimicrobial use, serious bacterial infections, trough IgG levels, acute rejection, spirometry, and mortality in each period. The definitions of infectious end points were drawn from an FDA draft document. [15] The necessary criteria were collected prospectively and all infectious events were determined with blinding to the treatment period.

Statistical Analysis

Generalized estimating equations with a compound symmetry covariance structure and logit link were used to estimate odds ratios. Linear mixed effects modeling with an autoregressive covariance structure were used to assess differences in lung function and IgG levels between treatment arms. Models included fixed effects for drug and period. Subject was included as a random effect. Least squares means and 95% confidence intervals for continuous outcomes are reported. Paired sample analysis was performed secondarily.

In order to detect a reduction in the mean number of bacterial infections/patient by one standard deviation over three months with 80% power at an α level of 0.05, we estimated that we would need 10 subjects. This effect estimate was similar to the difference between patients with and without HGG in prior studies. [9] The crossover design of the trial, in which each subject serves as his or
her own control, allows sufficient power for the detection of a clinically significant effect of IVIG with only a small number of patients and is the major strength of this design. For example, a sample size of 10 patients in a crossover trial has more power to detect differences than double the sample size using a parallel group design (i.e., randomizing 10 patients to IVIG and 10 patients to placebo). As we did not have multiple bacterial infections per patient (see below), the power of the study was less than anticipated.

The primary analysis proceeded according to the intent-to-treat principle. All randomized participants were analyzed in their originally assigned group whether or not they discontinued study drug. P values \(0.05\) were considered significant. Analyses were performed using SAS 9.2 (SAS Institute, Cary, NC). There were no interim analyses or stopping rules planned a priori for the trial.

Results

We screened 237 lung transplant recipients between January 2005 and July 2008 (Figure 1). Eleven subjects were eligible and randomized, and 10 completed all study assessments. One subject discontinued the interventions because of inability to comply with the schedule of study visits.

Participant characteristics are shown in Table 1. The mean age was 55 years (range 28 to 66 years) and six (55\%) were male. Most were non-Hispanic white. Six underwent lung transplantation for COPD and ten had undergone bilateral transplantation. The median time from transplantation to enrollment was 187 days (interquartile range 153 to 660 days). Five study participants (45\%) were taking valganciclovir for prophylaxis against cytomegalovirus. The median baseline IgG level for the study sample at randomization was 487.5 g/dl (IQR 423.5 to 513.8 g/dl), showing the variability over time in IgG levels (as all patients had IgG levels \(\geq 500\) g/dl on two assessments at least one month apart within three months before enrollment).

Subjects received the study treatments in the assigned order. One participant experienced chills, flushing, and nausea during infusion of IVIG. No other infusion-related adverse events occurred. Study drug was discontinued in one subject because of inability to comply with study visits. There were no period or carryover effects.

During the IVIG period, there were three bacterial infections (in three patients) compared to the placebo period, when there was one bacterial infection (in one patient) (odds ratio (OR) 3.5, 95\% CI 0.4 to 27.6, \(p=0.24\); Table 2). Paired sample analyses showed similar results (data not shown). Similarly, there were non-

---

Figure 1. Study flow.

[Image: Study flow diagram]

doi:10.1371/journal.pone.0103908.g001
significant increases in overall infections (IVIG-7 vs. placebo-3, OR 2.7, 95% CI 0.95 to 7.6, p = 0.06), antibiotic initiation (IVIG-9 vs. placebo-8, OR 1.4, 9% CI 0.3 to 6.0, p = 0.61), and hospitalization (IVIG-3 vs. placebo-1, OR 3.5, 95% CI 0.2 to 51.2, p = 0.37; Table 2) during the IVIG period compared to the placebo period. IVIG had no significant effect on lung function over three months (Table 3). As expected, the administration of IVIG significantly increased IgG levels throughout the treatment period compared to placebo (Table 3; Figure 2).

Table 4 shows the adverse events during the IVIG and placebo periods. Five serious adverse events occurred during the study, and four during a treatment period. Three (pancreatitis, vitreous hemorrhage, and E. coli pneumonia) occurred during the IVIG period and one (hospital admission for thymoglobulin infusion) during the placebo period. There was a hospitalization for a fall during the washout period. The most common adverse events were bronchoscopy (in >50% of participants in both periods). Cough and neck stiffness were more common during IVIG periods.

Discussion

To our knowledge, this is the first randomized, double-blind, placebo-controlled clinical trial of IVIG for HGG after lung transplantation. In a crossover design, we did not find a significant impact of IVIG on bacterial infections or other infectious episodes, despite observing expected increases in IgG levels following IVIG administration. Adverse events were mild and common during both IVIG and placebo periods.

Previous studies have shown associations between the presence of HGG after lung transplant and worse outcomes. We previously demonstrated that lung transplant recipients with severe HGG (IgG <400 mg/dl) had a higher cumulative incidence of pneumonia (63%) compared to that of recipients without HGG (18%), (p = 0.01), but there was no significant increase in the risk of CMV disease. [8] Those with severe HGG also had an increased risk of death. The incidence of severe HGG was about 15% in our prior studies, [7,8] however other investigators have demonstrated even higher prevalences of HGG after lung transplantation. [9] A recent study in pediatric lung transplant recipients found an association between HGG and the risk of infections and hospitalization. [16] More recently, lower post-transplant IgG levels were associated with an increased risk of BOS [6].

Table 1. Participant characteristics.

| Characteristic | Value |
|---------------|-------|
| No.           | 11    |
| Age           | 60 (28 to 66) |
| Male          | 6     |
| Race/ethnicity|       |
| Non-Hispanic white | 10     |
| Hispanic white | 1     |
| Height, cm    | 168 (140 to 183) |
| Weight, kg    | 68 (52 to 88) |
| Pre-transplant diagnosis |  |
| Chronic obstructive pulmonary disease | 6 |
| Interstitial lung disease | 2 |
| Cystic fibrosis | 1 |
| Pulmonary arterial hypertension | 2 |
| Transplant procedure |  |
| Bilateral | 10 |
| Single | 1 |
| Days since transplantation | 187 (119 to 1330) |
| Serum creatinine, mg/dl | 1.3 (0.9 to 1.8) |
| Immunosuppressive medications |  |
| Tacrolimus | 9 |
| Cyclosporine | 2 |
| Azathioprine | 5 |
| Mycophenolate mofetil | 6 |
| Prednisone | 11 |
| Forced vital capacity, % predicted | 92 (60 to 112) |
| Forced expiratory volume in 1 sec, % predicted | 109 (65 to 121) |
| Forced expiratory volume in 1 sec/Forced vital capacity ratio, % | 88 (72 to 100) |
| Forced expiratory flow 25–75, % predicted | 128 (50 to 270) |

Data are median (range) and frequency.
doi:10.1371/journal.pone.0103908.t001
Figure 2. Box (interquartile range) and whisker plots of serum IgG levels during the IVIG period (red) and placebo period (white). doi:10.1371/journal.pone.0103908.g002

Table 2. Outcomes.

|                               | No. of events occurring during IVIG treatment period | No. of events occurring during placebo treatment period | Odds ratio (IVIG vs. placebo) | 95% confidence interval | P value |
|-------------------------------|------------------------------------------------------|--------------------------------------------------------|-------------------------------|-------------------------|---------|
| Bacterial infection           | 3                                                    | 1                                                      | 3.5                           | 0.4 to 27.6             | 0.24    |
| Viral infection               | 2                                                    | 2                                                      | 0.8                           | 0.1 to 5.9              | 0.87    |
| Fungal infection              | 2                                                    | 0                                                      | --                            | --                      | --      |
| Any infection                 | 7                                                    | 3                                                      | 2.7                           | 0.95 to 7.6             | 0.06    |
| Positive culture              | 4                                                    | 2                                                      | 2.0                           | 0.4 to 9.3              | 0.37    |
| Antibiotic initiation         | 9                                                    | 8                                                      | 1.4                           | 0.3 to 6.0              | 0.61    |
| Bronchoscopy                  | 7                                                    | 6                                                      | 1.3                           | 0.7 to 2.4              | 0.47    |
| Hospitalization               | 3                                                    | 1                                                      | 3.5                           | 0.2 to 51.2             | 0.37    |
| Acute rejection               | 0                                                    | 0                                                      | --                            | --                      | --      |
| Lymphocytic bronchiolitis     | 0                                                    | 0                                                      | --                            | --                      | --      |

doi:10.1371/journal.pone.0103908.t002
IVIG is the current standard in clinical practice for replacement therapy of patients with primary immunodeficiency states. [17] Currently, IVIG is FDA approved for treatment of primary humoral immunodeficiency, Kawasaki syndrome, chronic lymphocytic leukemia and bone marrow transplant recipients with recurrent infections and idiopathic thrombocytopenic purpura.

| Table 3. Least square means (95% confidence interval) for spirometry value and serum IgG levels after IVIG and placebo. |
|---------------------------------------------------------------|
| **IVIG** | **Placebo** | **P value** |
| Forcely vital capacity, % predicted | 88.8 (86.6–91.1) | 89.7 (87.4–92.0) | 0.51 |
| Forcely expiratory volume in 1 sec, % predicted | 95.3 (92.2–98.3) | 95.6 (92.5–98.7) | 0.84 |
| Forcely expiratory volume in 1 sec/forcely vital capacity ratio, % | 86.9 (84.6–89.1) | 85.3 (83.0–87.6) | 0.14 |
| Forcely expiratory flow 25–75, % predicted | 125.0 (114.6–135.4) | 119.0 (108.3–129.5) | 0.14 |
| IgG, mg/dl | 765.3 (720.1–810.6) | 486.3 (441.0–531.5) | <0.001 |

Table 4. Adverse events.

| Event | **IVIG** | **Placebo** | **Washout** |
|-------|---------|-------------|-------------|
| Any AE | 11 (100%) | 11 (100%) | 11 (100%) |
| Serious adverse event | | | |
| Any SAE | 3 (27%) | 1 (9%) | 1 (9%) |
| Infusion-related AEs* | | | |
| Any infusion-related AE | 1 (9%) | 0 (0%) | – |
| Chills | 1 (9%) | 0 (0%) | – |
| Flushing | 1 (9%) | 0 (0%) | – |
| Nausea | 1 (9%) | 0 (0%) | – |
| Infectious | | | |
| Fever | 2 (18%) | 0 (0%) | 2 (18%) |
| Night sweats | 0 (0%) | 2 (18%) | 0 (0%) |
| Bronchoscopy | 7 (64%) | 6 (54%) | 7 (64%) |
| Pulmonary | | | |
| Dyspnea | 1 (9%) | 1 (9%) | 2 (18%) |
| Cough | 2 (18%) | 1 (9%) | 1 (9%) |
| Sputum production | 1 (9%) | 1 (9%) | 1 (9%) |
| Cardiac | | | |
| Palpitations | 1 (9%) | 1 (9%) | 1 (9%) |
| Pedal edema | 0 (0%) | 3 (27%) | 0 (0%) |
| Neurological | | | |
| Headache | 2 (18%) | 3 (27%) | 0 (0%) |
| Stiff neck | 2 (18%) | 0 (0%) | 1 (9%) |
| Gastrointestinal | | | |
| Urinary frequency | 1 (9%) | 2 (18%) | 0 (0%) |
| Pancreatitis | 1 (9%) | 0 (0%) | 0 (0%) |
| Other | | | |
| Diarrhea | | | |
| Abdominal discomfort | 1 (9%) | 2 (18%) | 0 (0%) |
| Heartburn/GER | 1 (9%) | 1 (9%) | 0 (0%) |
| Musculoskeletal pain | 2 (18%) | 2 (18%) | 0 (0%) |
| Acute kidney injury | 1 (9%) | 0 (0%) | 0 (0%) |
| Vitreous hemorrhage | 1 (9%) | 0 (0%) | 0 (0%) |

*AEs with more than 1 occurrence during the study (except for infusion related AEs, acute kidney injury, pancreatitis, and vitreous hemorrhage).

doi:10.1371/journal.pone.0103908.t004
While supplementation using IVIG in HGG after solid organ transplantation would be presumed to be effective, there are several reasons why it may not be. Organ transplant recipients receive a medical regimen that not only reduces B cell function (and antibody production), but also T cell function. HGG might be an epiphenomenon of reduced T cell function and merely replacing antibodies might not improve defenses against infection.

To our knowledge, there is only one other RCT of immunoglobulin replacement for HGG in thoracic organ transplantation. Yamani et al. studied the use of CytoGam in patients with IgG levels between 350 and 500 mg/dl in a randomized, double-blind placebo controlled trial with 13 patients randomized to CytoGam and 10 patients randomized to placebo (5% dextrose). [18] An average of only 1.4 doses were administered per patient, without a standard regimen. The investigators found a decrease in the number of episodes of CMV disease, but no other differences between the groups. These results may not be generalizable as this study 1) used CytoGam in patients who received valganciclovir for CMV prophylaxis for only 4 weeks after transplantation, 2) on average only administered 1–2 doses of study drug for the entire study period, 3) only showed an effect on CMV infection (defined as a positive CMV PCR with fever, malaise, leukopenia, or other evidence of organ disease), and 4) demonstrated no effect on bacterial infections. These data may be difficult to extrapolate to the chronic use of IVIG in lung transplant patients with HGG receiving more prolonged CMV prophylaxis.

Our study had several limitations. While the crossover design provided more power than we would have had with >20 subjects studied in a parallel design, there were few outcomes and our findings could very well be attributable to inadequate power. For the crossover design to be valid, we needed to ensure clinical stability over the time of both treatment periods, necessarily limiting the duration of each. Longer studies with greater numbers of patients would be necessary to detect smaller differences in outcomes. The primary statistical analysis may be anti-conservative in small samples, however no differences in the primary end point were seen and paired sample analyses were similar. We recruited patients with low IgG levels documented twice over a short period of time. Even so, some of the patients in the study had IgG levels >500 mg/dl at the time of randomization and during the placebo period. This was not attributable to a carryover effect (i.e., the effect of IVIG treatment during the first period continuing into the second period), but likely reflects the variable nature of IgG levels over time. While reflecting the “real world” application of IVIG (i.e., some patients clinically diagnosed with HGG based on two IgG levels in whom IVIG might be prescribed will go on to have IgG levels which are higher), it is possible that IgG levels >500 mg/dl during the placebo period could have led to bias to the null, even though the study subjects had significantly higher levels of IgG at every time point during treatment with IVIG. Finally, one participant dropped out early in the first period, which could have reduced power as well.

In summary, monthly IVIG therapy did not reduce the incidence of bacterial or other infections compared to placebo over three months in stable adult lung transplant recipients with HGG. Our results do not support the routine clinical use of IVIG in patients with HGG after lung transplant. However, it is unknown whether IVIG may be effective for lung transplant recipients with HGG and repeated or refractory bacterial, fungal, or viral infections.

Supporting Information

Checklist S1 CONSORT checklist. (DOC)
Protocol S1 Study Protocol. (DOC)

Author Contributions
Conceived and designed the experiments: DJL SMA SMK NP DR. Performed the experiments: DJL SMA SMK NP DR. Analyzed the data: DJL SMA SMK. Wrote the paper: DJL SMA SMK NP DR.

References

1. Kotloff RM, Thabut G (2011) Lung transplantation. Am J Respir Crit Care Med 184: 159–171.
2. Aguilar-Guisado M, Givalda J, Ussetti P, Ramos A, Morales P, et al. (2007) Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 7: 1899–1906.
3. de Bruyn G, Whelan TP, Mulligan MS, Raghu G, Limaye AP (2004) Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 4: 1366–1371.
4. Husain S, Chan KM, Palmer SM, Hadjiadhis D, Humar A, et al. (2006) Bacteremia in lung transplant recipients in the current era. Am J Transplant 6: 3000–3007.
5. Remund KF, Best M, Egan JJ (2009) Infections relevant to lung transplantation. Prog Am Thorac Soc 6: 94–106.
6. Chambers DC, Davies B, Mathews A, Yerkovich ST, Hopkins PM (2013) Bronchiolitis obliterans syndrome, hypogammaglobulinemia, and infectious complications of lung transplantation. J Heart Lung Transplant 32: 36–43.
7. Yip NH, Lederer DJ, Kawat SM, Wilt JS, D’Ocajo F, et al. (2006) Immunglobulin G levels before and after lung transplantation. Am J Respir Crit Care Med 173: 917–921.
8. Kawat SM, Shah I, Wilt JS, Dwyer E, Maami PA, et al. (2005) Risk factors and outcomes of hypogammaglobulinemia after lung transplantation. Transplantation 71: 552–553.
9. Godlharb NS, Avery RK, Greenson M, Mehta AC, Schilz R, et al. (2001) Hypogammaglobulinemia in lung transplant recipients. Transplantation 71: 242–246.
10. Foreman DF, Kabir AC, Qiao F, Schmidt CM, Samulkovsky U (2013) What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant 13: 2601–2610.
11. Yamani MH, Avery RK, Mawhorter SD, Young JR, Ratliff NB, et al. (2001) Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection. J Heart Lung Transplant 20: 425–430.
12. Doron S, Rathazer R, Werner BG, Rabson A, Snyderman DR (2006) Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 81: 697–703.
13. Fernandez-Ruiz M, Lopez-Medrano F, Varela-Pena P, Lora-Pablos D, Garcia-Reyne A, et al. (2012) Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant 12: 2763–2773.
14. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, et al. (2006) Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117: S525–553.
15. Food and Drug Administration. Guidance for Industry: Evaluating Clinical Studies of Antimicrobials in the Division of Anti-Infective Drug Products (draft 02/1997). Center for Drug Evaluation and Research (CDER). Rockville, MD. Available at the FDA website: Available: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064980.htm. Accessed 2013 Sep 3.
16. Robertson J, Ehlert M, Osz EU, Galen F, Schecter M, et al. (2009) Hypogammaglobulinemia: Incidence, risk factors, and outcomes following pediatric lung transplantation. Pediatric transplantation 13: 754–759.
17. Anonymous (1990) NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 264: 3189–3193.
18. Yamani MH, Avery R, Mawhorter SD, McNeill A, Cook D, et al. (2005) The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study. J Heart Lung Transplant 24: 1766–1769.